← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Vistagen Therapeutics, Inc.
South San Francisco, CA
$11,186,113
Total funding
8
Grants
Funding over time
peak $2.5M · FY2005–10$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$11,186,113 · 8
By mechanism
R44$6,295,229 · 2
U01$3,620,249 · 1
R43$1,270,635 · 5
Investigators at Vistagen Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Clinical Development of 4-Cl-KYN to Treat Pain$2,469,281
R44 · FY2009 · DA
Clinical Development of 4-Cl-KYN to Treat Pain$1,714,903
R44 · FY2010 · DA
Preclinical Development of 4-CI-KYN to Treat Epilepsy$1,229,375
U01 · FY2005 · NS
Preclinical Development of 4-CI-KYN to Treat Epilepsy$1,196,369
U01 · FY2007 · NS
Preclinical Development of 4-CI-KYN to Treat Epilepsy$1,194,505
U01 · FY2006 · NS
DEVELOPMET OF STEM CELL TECHNOLOGIES FOR TOXICOLOGY$948,465
R44 · FY2002 · GM
DEVELOPMET OF STEM CELL TECHNOLOGIES FOR TOXICOLOGY$742,682
R44 · FY2003 · GM
Clinical Development of 4-Cl-KYN to Treat Pain$419,898
R44 · FY2010 · DA
Development of 4-Chlorokynurenine to Treat Epilepsy$380,752
R43 · FY2004 · NS
STEM CELL TECHNOLOGIES FOR TOXICOLOGY ASSESSMENT$249,754
R43 · FY2000 · GM
IN VITRO STEM CELL ASSAY FOR DRUG TOXICOLOGY ASSESSMENT$219,757
R43 · FY2001 · CA
Preclinical Development of 4-CI-KYN to Treat Pain$196,894
R43 · FY2005 · DA
Multivariate Analysis for Molecular Toxicology Screening$185,478
R43 · FY2002 · CA
Development of 4-Chlorokynurenine to Treat Epilepsy$38,000
R43 · FY2004 · NS